Many Charles River Laboratories International, Inc.(CRL) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Charles River Laboratories was Upgraded by Goldman to Neutral on Dec 16, 2016. Company shares were Upgraded by Barclays on Nov 30, 2016 to Equal Weight, Raises Price Target to $ 77 from a previous price target of $65 .
Company has reported several Insider transactions to the SEC, on Feb 1, 2017, David P Johst (Corporate Executive VP) sold 13,950 shares at 78.00 per share price.On Dec 5, 2016, Stephen D Chubb (director) sold 4,564 shares at 71.57 per share price.On Nov 29, 2016, C Richard Reese (director) sold 4,539 shares at 71.93 per share price.
Charles River Laboratories Last issued its quarterly earnings results on Feb 14, 2017. The company reported $1.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $1.11. The company had revenue of $466.80 million for the quarter, compared to analysts expectations of $441.73 million. The companys revenue was up 31.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.
Charles River Laboratories International, Inc. (NYSE:CRL) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2 by 16 Brokerage Firm. 9 Wall Street Firms have rated the stock as a strong buys. 6 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.
Charles River Laboratories International, Inc. (NYSE:CRL): According to 11 Analysts, The short term target price has been estimated at $ 88.05.The target price could deviate by a maximum of $7.59 from the forecast price. In the near term, the target price could hit a high of $98 and a low of $ 77.
Charles River Laboratories International, Inc. (NYSE:CRL) rose 7.86% or 6.48 points on Tuesday and made its way into the gainers of the day. After trading began at $86.49 the stock was seen hitting $89.585 as a peak level and $85 as the lowest level. The stock ended up at $88.95. The daily volume was measured at 1,207,159 shares. The 52-week high of the share price is $89.585 and the 52-week low is $67.2. The company has a market cap of $4,210 million.
Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years.